Bristol-Myers Squibb Says Phase III Trials Of ORENCIA In RA Patients Show Positive Results - Update

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

(RTTNews) - Bristol-Myers Squibb Co. (BMY | charts | news | PowerRating), a manufacturer of pharmaceuticals and health care products, on Monday said that the results from two Phase III pivotal trials showed ORENCIA or abatacept improved daily activity participation, physical and social-role independence and sleep quality in adult rheumatoid arthritis patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs, such as methotrexate or tumor necrosis factor antagonists.

The New York-based company presented these data from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA.

The chronic nature of rheumatoid arthritis can have a significant impact on a person's health-related quality of life, including independence, ability to perform daily activities and sleep quality.

ORENCIA is indicated in the United States for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists. ORENCIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists.

BMY is trading at $28.27, down $0.02 or 0.07% on a volume of 4.89 million shares.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2007 RealTimeTraders.com, Inc. All Rights Reserved

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index